Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) reported a net profit of SAR 153.4 million for the first half of 2017, a 19.9 percent year-on-year (YoY) increase, thanks to a 13.3 percent decline in sales and marketing expenses.
The company also recorded SAR 46.1 million gains from selling securities.
| Item | 6m 2016 | 6m 2017 | Change |
|---|---|---|---|
| Revenues | 661.75 | 697.74 | 5.4 % |
| Gross Income | 377.84 | 368.71 | (2.4 %) |
| Operating Income | 80.72 | 99.43 | 23.2 % |
| Net Income | 128.53 | 147.78 | 15.0 % |
| Average Shares | 120.00 | 120.00 | - |
| EPS (Riyals) | 1.07 | 1.23 | 15.0 % |
Net profit for the second quarter grew by 35.8 percent YoY to SAR 53.4 million, backed by lower selling, general and administrative expenses.
When compared to the previous quarter, the pharmaceutical producer’s net profit declined by 46.6 percent, due to a drop in gross profit and sales despite lower operating expenses.
| Item | Q2 2016 | Q2 2017 | Change |
|---|---|---|---|
| Revenues | 339.54 | 304.63 | (10.3 %) |
| Gross Income | 183.58 | 156.13 | (15.0 %) |
| Operating Income | 27.50 | 49.40 | 79.6 % |
| Net Income | 39.61 | 46.56 | 17.5 % |
| Average Shares | 120.00 | 120.00 | - |
| EPS (Riyals) | 0.33 | 0.39 | 17.5 % |
| Item | Q1 2017 | Q2 2017 | Change |
|---|---|---|---|
| Revenues | 393.10 | 304.63 | (22.5 %) |
| Gross Income | 212.58 | 156.13 | (26.6 %) |
| Operating Income | 50.03 | 49.40 | (1.3 %) |
| Net Income | 101.22 | 46.56 | (54.0 %) |
| Average Shares | 120.00 | 120.00 | - |
| EPS (Riyals) | 0.84 | 0.39 | (54.0 %) |
| Period | Revenues | Change | Gross Income | Change | Net Income | Change | EPS(Riyal) |
|---|---|---|---|---|---|---|---|
| Q1 2008 | 220.58 | 8.5 % | 99.57 | 9.4 % | 40.93 | 3.6 % | 0.40 |
| Q2 2008 | 211.66 | 1.1 % | 74.78 | 12.5 % | 34.24 | 51.7 % | 0.34 |
| Q3 2008 | 145.45 | (2.6 %) | 74.34 | 11.2 % | 15.62 | (41.1 %) | 0.15 |
| Q4 2008 | 294.26 | 24.8 % | 114.28 | 11.7 % | 37.48 | 12.6 % | 0.37 |
| 2008 | 871.94 | 9.3 % | 362.97 | 11.1 % | 128.27 | 5.2 % | 1.26 |
| Q1 2009 | 257.88 | 16.9 % | 108.57 | 9.0 % | 42.69 | 4.3 % | 0.42 |
| Q2 2009 | 229.00 | 8.2 % | 81.53 | 9.0 % | 37.81 | 10.4 % | 0.37 |
| Q3 2009 | 171.15 | 17.7 % | 72.49 | (2.5 %) | 15.84 | 1.4 % | 0.16 |
| Q4 2009 | 292.71 | (0.5 %) | 157.00 | 37.4 % | 58.48 | 56.0 % | 0.58 |
| 2009 | 950.74 | 9.0 % | 419.59 | 15.6 % | 154.81 | 20.7 % | 1.53 |
| Q1 2010 | 274.33 | 6.4 % | 118.90 | 9.5 % | 45.32 | 6.2 % | 0.38 |
| Q2 2010 | 252.34 | 10.2 % | 100.50 | 23.3 % | 43.09 | 14.0 % | 0.36 |
| Q3 2010 | 191.40 | 11.8 % | 85.88 | 18.5 % | 18.07 | 14.1 % | 0.15 |
| Q4 2010 | 319.57 | 9.2 % | 181.12 | 15.4 % | 70.04 | 19.8 % | 0.58 |
| 2010 | 1,037.64 | 9.1 % | 486.40 | 15.9 % | 176.52 | 14.0 % | 1.47 |
| Q1 2011 | 252.08 | (8.1 %) | 123.51 | 3.9 % | 45.71 | 0.9 % | 0.38 |
| Q2 2011 | 292.08 | 15.7 % | 123.61 | 23.0 % | 60.75 | 41.0 % | 0.51 |
| Q3 2011 | 209.24 | 9.3 % | 106.76 | 24.3 % | 29.75 | 64.6 % | 0.25 |
| Q4 2011 | 375.82 | 17.6 % | 206.69 | 14.1 % | 74.06 | 5.7 % | 0.62 |
| 2011 | 1,129.22 | 8.8 % | 560.57 | 15.2 % | 211.44 | 19.8 % | 1.76 |
| Q1 2012 | 303.14 | 20.3 % | 153.21 | 24.0 % | 56.45 | 23.5 % | 0.47 |
| Q2 2012 | 286.64 | (1.9 %) | 140.91 | 14.0 % | 90.14 | 48.4 % | 0.75 |
| Q3 2012 | 227.40 | 8.7 % | 113.28 | 6.1 % | 32.33 | 8.7 % | 0.27 |
| Q4 2012 | 365.97 | (2.6 %) | 211.16 | 2.2 % | 53.73 | (27.5 %) | 0.45 |
| 2012 | 1,183.15 | 4.8 % | 618.56 | 10.3 % | 232.65 | 10.0 % | 1.94 |
| Q1 2013 | 361.37 | 19.2 % | 184.62 | 20.5 % | 63.15 | 11.9 % | 0.53 |
| Q2 2013 | 344.22 | 20.1 % | 179.12 | 27.1 % | 113.71 | 26.1 % | 0.95 |
| Q3 2013 | 222.91 | (2.0 %) | 118.64 | 4.7 % | 34.19 | 5.8 % | 0.28 |
| Q4 2013 | 382.01 | 4.4 % | 226.14 | 7.1 % | 57.01 | 6.1 % | 0.48 |
| 2013 | 1,310.50 | 10.8 % | 708.52 | 14.5 % | 266.82 | 14.7 % | 2.22 |
| Q1 2014 | 405.21 | 12.1 % | 206.72 | 12.0 % | 91.17 | 44.4 % | 0.76 |
| Q2 2014 | 371.14 | 7.8 % | 193.14 | 7.8 % | 97.72 | (14.1 %) | 0.81 |
| Q3 2014 | 266.02 | 19.3 % | 134.45 | 13.3 % | 36.69 | 7.3 % | 0.31 |
| Q4 2014 | 431.06 | 12.8 % | 261.80 | 15.8 % | 91.29 | 60.1 % | 0.76 |
| 2014 | 1,470.19 | 12.2 % | 794.54 | 12.1 % | 316.85 | 18.8 % | 2.64 |
| Q1 2015 | 432.20 | 6.7 % | 225.86 | 9.3 % | 99.39 | 9.0 % | 0.83 |
| Q2 2015 | 435.80 | 17.4 % | 210.95 | 9.2 % | 237.63 | 143.2 % | 1.98 |
| Q3 2015 | 308.27 | 15.9 % | 131.32 | (2.3 %) | 29.16 | (20.5 %) | 0.24 |
| Q4 2015 | 520.38 | 20.7 % | 266.38 | 1.7 % | (9.12) | (110.0 %) | (0.08) |
| 2015 | 1,705.05 | 16.0 % | 848.60 | 6.8 % | 357.05 | 12.7 % | 2.98 |
| Q1 2016 | 322.20 | (25.4 %) | 194.26 | (14.0 %) | 88.91 | (10.5 %) | 0.74 |
| Q2 2016 | 339.54 | (22.1 %) | 183.58 | (13.0 %) | 39.61 | (83.3 %) | 0.33 |
| Q3 2016 | 257.21 | (16.6 %) | 140.54 | 7.0 % | 4.76 | (83.7 %) | 0.04 |
| Q4 2016 | 339.59 | (34.7 %) | 194.16 | (27.1 %) | 143.48 | 1673.8 % | 1.20 |
| 2016 | 1,258.55 | (26.2 %) | 712.54 | (16.0 %) | 276.76 | (22.5 %) | 2.31 |
| Q1 2017 | 393.10 | 22.0 % | 212.58 | 9.4 % | 101.22 | 13.8 % | 0.84 |
| Q2 2017 | 304.63 | (10.3 %) | 156.13 | (15.0 %) | 46.56 | 17.5 % | 0.39 |
| Period | Revenues | Change | Gross Income | Change | Net Income | Change | EPS(Riyal) |
|---|---|---|---|---|---|---|---|
| 2007 | 797.75 | 9.6 % | 326.62 | 5.9 % | 121.87 | 16.0 % | 1.20 |
| 2008 | 871.94 | 9.3 % | 362.97 | 11.1 % | 128.27 | 5.2 % | 1.26 |
| 2009 | 950.74 | 9.0 % | 419.59 | 15.6 % | 154.81 | 20.7 % | 1.53 |
| 2010 | 1,037.64 | 9.1 % | 486.40 | 15.9 % | 176.52 | 14.0 % | 1.47 |
| 2011 | 1,129.22 | 8.8 % | 560.57 | 15.2 % | 211.44 | 19.8 % | 1.76 |
| 2012 | 1,183.15 | 4.8 % | 618.56 | 10.3 % | 232.65 | 10.0 % | 1.94 |
| 2013 | 1,310.50 | 10.8 % | 708.52 | 14.5 % | 266.82 | 14.7 % | 2.22 |
| 2014 | 1,470.19 | 12.2 % | 794.54 | 12.1 % | 316.85 | 18.8 % | 2.64 |
| 2015 | 1,705.05 | 16.0 % | 848.60 | 6.8 % | 357.05 | 12.7 % | 2.98 |
| 2016 | 1,258.55 | (26.2 %) | 712.54 | (16.0 %) | 276.76 | (22.5 %) | 2.31 |
| Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
|---|---|---|---|
| Q1 2008 | 41.13 % | 15.70 % | 15.13 % |
| Q2 2008 | 42.03 % | 16.67 % | 16.57 % |
| Q3 2008 | 43.15 % | 16.47 % | 15.83 % |
| Q4 2008 | 41.63 % | 16.30 % | 15.25 % |
| 2008 | 41.63 % | 16.30 % | 15.16 % |
| Q1 2009 | 40.91 % | 16.13 % | 14.83 % |
| Q2 2009 | 40.87 % | 16.44 % | 14.89 % |
| Q3 2009 | 39.57 % | 15.73 % | 14.07 % |
| Q4 2009 | 44.13 % | 18.49 % | 16.63 % |
| 2009 | 44.13 % | 18.49 % | 16.63 % |
| Q1 2010 | 44.45 % | 18.88 % | 16.94 % |
| Q2 2010 | 45.32 % | 18.93 % | 17.07 % |
| Q3 2010 | 45.73 % | 18.73 % | 16.95 % |
| Q4 2010 | 46.88 % | 18.85 % | 17.32 % |
| 2010 | 46.88 % | 18.85 % | 17.32 % |
| Q1 2011 | 48.36 % | 18.99 % | 17.42 % |
| Q2 2011 | 48.73 % | 19.12 % | 18.44 % |
| Q3 2011 | 49.86 % | 19.99 % | 19.22 % |
| Q4 2011 | 49.64 % | 19.57 % | 18.62 % |
| 2011 | 49.64 % | 19.65 % | 18.72 % |
| Q1 2012 | 50.01 % | 19.86 % | 18.73 % |
| Q2 2012 | 51.72 % | 20.36 % | 21.31 % |
| Q3 2012 | 51.47 % | 20.54 % | 21.21 % |
| Q4 2012 | 52.28 % | 19.56 % | 19.66 % |
| 2012 | 52.28 % | 19.56 % | 19.66 % |
| Q1 2013 | 52.36 % | 19.26 % | 19.28 % |
| Q2 2013 | 52.98 % | 18.87 % | 20.24 % |
| Q3 2013 | 53.58 % | 18.66 % | 20.45 % |
| Q4 2013 | 54.06 % | 18.26 % | 20.45 % |
| 2013 | 54.06 % | 18.16 % | 20.36 % |
| Q1 2014 | 53.95 % | 17.92 % | 21.86 % |
| Q2 2014 | 53.91 % | 17.74 % | 20.28 % |
| Q3 2014 | 53.39 % | 16.79 % | 19.84 % |
| Q4 2014 | 54.03 % | 18.15 % | 21.50 % |
| 2014 | 54.04 % | 18.15 % | 21.55 % |
| Q1 2015 | 54.34 % | 18.90 % | 21.67 % |
| Q2 2015 | 53.23 % | 18.31 % | 20.04 % |
| Q3 2015 | 51.63 % | 17.40 % | 19.05 % |
| Q4 2015 | 49.19 % | 17.17 % | 19.11 % |
| 2015 | 49.77 % | 16.85 % | 19.02 % |
| Q1 2016 | 50.60 % | 15.90 % | 18.80 % |
| Q2 2016 | 52.04 % | 15.52 % | 16.88 % |
| Q3 2016 | 54.52 % | 15.09 % | 15.79 % |
| Q4 2016 | 56.62 % | 10.25 % | 5.68 % |
| 2016 | 56.62 % | 10.25 % | 5.68 % |
| Q1 2017 | 54.97 % | 9.67 % | 3.99 % |
| Q2 2017 | 54.34 % | 11.85 % | 4.64 % |
| Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
|---|---|---|---|
| 2007 | 40.94 % | 15.79 % | 15.28 % |
| 2008 | 41.63 % | 16.30 % | 15.16 % |
| 2009 | 44.13 % | 18.49 % | 16.63 % |
| 2010 | 46.88 % | 18.85 % | 17.32 % |
| 2011 | 49.64 % | 19.65 % | 18.72 % |
| 2012 | 52.28 % | 19.56 % | 19.66 % |
| 2013 | 54.06 % | 18.16 % | 20.36 % |
| 2014 | 54.04 % | 18.15 % | 21.55 % |
| 2015 | 49.77 % | 16.85 % | 19.02 % |
| 2016 | 56.62 % | 10.25 % | 5.68 % |
| Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
|---|---|---|---|
| Q1 2008 | 45.14 % | 22.16 % | 18.55 % |
| Q2 2008 | 35.33 % | 8.71 % | 16.39 % |
| Q3 2008 | 51.11 % | 19.82 % | 13.64 % |
| Q4 2008 | 38.84 % | 15.63 % | 12.74 % |
| Q1 2009 | 42.10 % | 20.70 % | 16.62 % |
| Q2 2009 | 35.60 % | 10.54 % | 16.51 % |
| Q3 2009 | 42.35 % | 15.37 % | 9.25 % |
| Q4 2009 | 53.64 % | 24.60 % | 21.04 % |
| Q1 2010 | 43.34 % | 21.92 % | 17.70 % |
| Q2 2010 | 39.83 % | 11.52 % | 17.08 % |
| Q3 2010 | 44.87 % | 14.68 % | 9.44 % |
| Q4 2010 | 56.68 % | 24.50 % | 21.92 % |
| Q1 2011 | 49.00 % | 22.74 % | 18.13 % |
| Q2 2011 | 42.32 % | 13.00 % | 20.80 % |
| Q3 2011 | 51.02 % | 19.57 % | 14.22 % |
| Q4 2011 | 55.00 % | 22.56 % | 19.71 % |
| Q1 2012 | 50.54 % | 23.32 % | 18.62 % |
| Q2 2012 | 49.16 % | 14.95 % | 31.45 % |
| Q3 2012 | 49.82 % | 20.53 % | 14.22 % |
| Q4 2012 | 57.70 % | 19.47 % | 14.68 % |
| Q1 2013 | 51.09 % | 21.68 % | 17.48 % |
| Q2 2013 | 52.04 % | 14.20 % | 33.03 % |
| Q3 2013 | 53.22 % | 19.34 % | 15.34 % |
| Q4 2013 | 59.20 % | 18.05 % | 14.92 % |
| Q1 2014 | 51.02 % | 20.19 % | 22.50 % |
| Q2 2014 | 52.04 % | 13.80 % | 26.33 % |
| Q3 2014 | 50.54 % | 13.97 % | 13.79 % |
| Q4 2014 | 60.73 % | 22.54 % | 21.18 % |
| Q1 2015 | 52.26 % | 22.70 % | 23.00 % |
| Q2 2015 | 48.40 % | 12.42 % | 19.81 % |
| Q3 2015 | 42.60 % | 9.85 % | 9.46 % |
| Q4 2015 | 51.19 % | 20.88 % | 21.02 % |
| Q1 2016 | 60.29 % | 18.36 % | 22.80 % |
| Q2 2016 | 54.07 % | 9.77 % | 11.67 % |
| Q3 2016 | 54.64 % | 6.30 % | 1.85 % |
| Q4 2016 | 57.18 % | 6.04 % | (13.65 %) |
| Q1 2017 | 54.08 % | 14.94 % | 14.01 % |
| Q2 2017 | 51.25 % | 19.02 % | 15.29 % |
| Period | Shares Outstanding (M) | EPS (Riyal) | Adjusted EPS (Riyal) | Book Value (BV) |
|---|---|---|---|---|
| Q1 2008 | 101.51 | 1.21 | 1.21 | 26.83 |
| Q2 2008 | 101.51 | 1.33 | 1.33 | 27.74 |
| Q3 2008 | 101.51 | 1.22 | 1.27 | 21.88 |
| Q4 2008 | 101.51 | 1.26 | 1.31 | 13.76 |
| Q1 2009 | 101.51 | 1.28 | 1.33 | 14.17 |
| Q2 2009 | 101.51 | 1.32 | 1.36 | 17.62 |
| Q3 2009 | 101.51 | 1.32 | 1.32 | 19.72 |
| Q4 2009 | 101.51 | 1.53 | 1.56 | 21.46 |
| Q1 2010 | 120.00 | 1.31 | 1.36 | 22.04 |
| Q2 2010 | 120.00 | 1.36 | 1.41 | 19.98 |
| Q3 2010 | 120.00 | 1.37 | 1.43 | 21.69 |
| Q4 2010 | 120.00 | 1.47 | 1.50 | 24.48 |
| Q1 2011 | 120.00 | 1.47 | 1.47 | 25.41 |
| Q2 2011 | 120.00 | 1.62 | 1.62 | 27.29 |
| Q3 2011 | 120.00 | 1.72 | 1.72 | 25.92 |
| Q4 2011 | 120.00 | 1.75 | 1.75 | 26.50 |
| Q1 2012 | 120.00 | 1.84 | 1.84 | 30.26 |
| Q2 2012 | 120.00 | 2.09 | 2.09 | 25.75 |
| Q3 2012 | 120.00 | 2.11 | 2.11 | 26.24 |
| Q4 2012 | 120.00 | 1.94 | 1.94 | 25.28 |
| Q1 2013 | 120.00 | 1.99 | 1.99 | 27.18 |
| Q2 2013 | 120.00 | 2.19 | 2.19 | 26.14 |
| Q3 2013 | 120.00 | 2.21 | 2.21 | 27.35 |
| Q4 2013 | 120.00 | 2.23 | 2.23 | 32.18 |
| Q1 2014 | 120.00 | 2.47 | 2.47 | 32.96 |
| Q2 2014 | 120.00 | 2.33 | 2.33 | 33.21 |
| Q3 2014 | 120.00 | 2.35 | 2.35 | 35.74 |
| Q4 2014 | 120.00 | 2.64 | 2.64 | 28.75 |
| Q1 2015 | 120.00 | 2.71 | 2.71 | 27.84 |
| Q2 2015 | 120.00 | 3.87 | 2.61 | 28.72 |
| Q3 2015 | 120.00 | 3.81 | 2.55 | 24.87 |
| Q4 2015 | 120.00 | 2.98 | 2.70 | 22.17 |
| Q1 2016 | 120.00 | 2.89 | 2.49 | 20.84 |
| Q2 2016 | 120.00 | 1.24 | 2.10 | 20.49 |
| Q3 2016 | 120.00 | 1.03 | 1.89 | 20.40 |
| Q4 2016 | 120.00 | 2.31 | 0.60 | 22.59 |
| Q1 2017 | 120.00 | 2.41 | 0.44 | 23.27 |
| Q2 2017 | 120.00 | 2.47 | 0.50 | 21.52 |
| Period | Shares Outstanding (M) | EPS (Riyal) | Adjusted EPS (Riyal) | Book Value (BV) |
|---|---|---|---|---|
| 2007 | 101.51 | 1.20 | 1.20 | 28.41 |
| 2008 | 101.51 | 1.26 | 1.30 | 13.76 |
| 2009 | 101.51 | 1.53 | 1.56 | 21.46 |
| 2010 | 120.00 | 1.47 | 1.50 | 24.48 |
| 2011 | 120.00 | 1.76 | 1.76 | 26.50 |
| 2012 | 120.00 | 1.94 | 1.94 | 25.28 |
| 2013 | 120.00 | 2.22 | 2.22 | 32.18 |
| 2014 | 120.00 | 2.64 | 2.64 | 28.75 |
| 2015 | 120.00 | 2.98 | 2.70 | 22.17 |
| 2016 | 120.00 | 2.31 | 0.60 | 22.59 |
| Period | P/E | Adjusted P/E | Price/book |
|---|---|---|---|
| Q1 2008 | 27.68 | 27.68 | 1.25 |
| Q2 2008 | 26.79 | 26.70 | 1.28 |
| Q3 2008 | 20.49 | 19.74 | 1.14 |
| Q4 2008 | 12.99 | 12.53 | 1.19 |
| Q1 2009 | 14.92 | 14.39 | 1.35 |
| Q2 2009 | 17.20 | 16.65 | 1.28 |
| Q3 2009 | 18.29 | 18.26 | 1.22 |
| Q4 2009 | 15.25 | 14.94 | 1.08 |
| Q1 2010 | 16.69 | 16.04 | 0.99 |
| Q2 2010 | 14.70 | 14.15 | 1.00 |
| Q3 2010 | 14.64 | 14.10 | 0.93 |
| Q4 2010 | 15.82 | 15.53 | 0.95 |
| Q1 2011 | 17.65 | 17.65 | 1.02 |
| Q2 2011 | 15.68 | 15.68 | 0.93 |
| Q3 2011 | 14.41 | 14.41 | 0.96 |
| Q4 2011 | 15.03 | 15.03 | 0.99 |
| Q1 2012 | 17.92 | 17.92 | 1.09 |
| Q2 2012 | 12.56 | 12.56 | 1.02 |
| Q3 2012 | 13.70 | 13.70 | 1.10 |
| Q4 2012 | 14.74 | 14.74 | 1.13 |
| Q1 2013 | 13.60 | 13.60 | 1.00 |
| Q2 2013 | 15.51 | 15.51 | 1.30 |
| Q3 2013 | 15.70 | 15.70 | 1.27 |
| Q4 2013 | 19.02 | 19.02 | 1.32 |
| Q1 2014 | 19.07 | 19.07 | 1.43 |
| Q2 2014 | 19.29 | 19.29 | 1.36 |
| Q3 2014 | 21.41 | 21.41 | 1.41 |
| Q4 2014 | 12.89 | 12.89 | 1.18 |
| Q1 2015 | 14.78 | 14.78 | 1.44 |
| Q2 2015 | 11.59 | 17.18 | 1.56 |
| Q3 2015 | 9.46 | 14.14 | 1.45 |
| Q4 2015 | 11.16 | 12.29 | 1.50 |
| Q1 2016 | 11.15 | 12.96 | 1.55 |
| Q2 2016 | 29.96 | 17.69 | 1.81 |
| Q3 2016 | 30.18 | 16.49 | 1.53 |
| Q4 2016 | 17.72 | 68.63 | 1.81 |
| Q1 2017 | 15.03 | 81.82 | 1.56 |
| Q2 2017 | 14.32 | 70.59 | 1.64 |
| Period | P/E | Adjusted P/E | Price/book |
|---|---|---|---|
| 2007 | 33.83 | 33.83 | 1.43 |
| 2008 | 12.99 | 12.60 | 1.19 |
| 2009 | 15.25 | 14.94 | 1.08 |
| 2010 | 15.82 | 15.53 | 0.95 |
| 2011 | 14.95 | 14.95 | 0.99 |
| 2012 | 14.74 | 14.74 | 1.13 |
| 2013 | 19.11 | 19.11 | 1.32 |
| 2014 | 12.89 | 12.89 | 1.18 |
| 2015 | 11.16 | 12.29 | 1.50 |
| 2016 | 17.72 | 68.63 | 1.81 |
Q2 2017
2017
| Period | Medical & Pharmaceutical production segment | Investment activity | Eliminations |
|---|---|---|---|
| Q1 2008 | 220.58 | - | - |
| Q2 2008 | 211.66 | - | - |
| Q3 2008 | 145.45 | - | - |
| Q4 2008 | 294.25 | - | - |
| Q1 2009 | 257.88 | - | - |
| Q2 2009 | 229.00 | - | - |
| Q3 2009 | 171.15 | - | - |
| Q4 2009 | 292.71 | - | - |
| Q1 2010 | 274.33 | - | - |
| Q2 2010 | 252.34 | - | - |
| Q3 2010 | 191.41 | - | - |
| Q4 2010 | 319.57 | - | - |
| Q1 2011 | 252.08 | - | - |
| Q2 2011 | 292.08 | - | - |
| Q3 2011 | 209.24 | - | - |
| Q4 2011 | 375.82 | - | - |
| Q1 2012 | 303.14 | - | - |
| Q2 2012 | 286.65 | - | - |
| Q3 2012 | 227.40 | - | - |
| Q4 2012 | 365.97 | - | - |
| Q1 2013 | 361.37 | - | - |
| Q2 2013 | 344.22 | - | - |
| Q3 2013 | 222.91 | - | - |
| Q4 2013 | 382.01 | - | - |
| Q1 2014 | 405.21 | - | - |
| Q2 2014 | 374.14 | - | - |
| Q3 2014 | 266.02 | - | - |
| Q4 2014 | 427.82 | - | - |
| Q1 2015 | 432.29 | 14.84 | - |
| Q2 2015 | 436.99 | 195.93 | - |
| Q3 2015 | 308.38 | 9.55 | - |
| Q4 2015 | 529.24 | - | - |
| Q1 2016 | 513.97 | 25.27 | - |
| Q2 2016 | 494.92 | 9.41 | - |
| Q3 2016 | 100.39 | 6.23 | - |
| Q4 2016 | 401.35 | 247.84 | - |
| Q1 2017 | 446.00 | 50.90 | (51.45) |
| Q2 2017 | 350.01 | 1.39 | (43.30) |
| Period | Medical & Pharmaceutical production segment | Investment activity | Eliminations |
|---|---|---|---|
| 2007 | 797.75 | - | - |
| 2008 | 871.94 | - | - |
| 2009 | 950.74 | - | - |
| 2010 | 1,037.64 | - | - |
| 2011 | 1,129.22 | - | - |
| 2012 | 1,183.15 | - | - |
| 2013 | 1,310.50 | - | - |
| 2014 | 1,470.19 | - | - |
| 2015 | 1,706.80 | 115.14 | - |
| 2016 | 1,510.63 | 288.74 | (244.41) |
| Item | Q2 2017 (e) | Q2 2017 (a) | Change |
|---|---|---|---|
| Average | 53.00 | 46.56 | (12.1 %) |
| Current | |
| Market Cap (M Riyal) | 3,444.00 |
| Enterprise Value (EV) (M) | 4,525.48 |
| Shares Outstanding ((M)) | 120.00 |
| EPS ( Riyal) (TTM) | (0.27) |
| Book Value (BV) ( Riyal) | 12.89 |
| Par Value ( Riyal) | 10.00 |
| Adjusted P/E (Last12) | Neg |
| P/E (TTM) | NEG |
| Price/book | 2.23 |
| Return on Average Assets (%) (TTM) | (0.76 ) |
| Return on Average Equity (%) (TTM) | (2.09 ) |
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}